三小汤治疗慢性阻塞性肺疾病合并心力衰竭临床研究

Treatment of Chronic Obstructive Pulmonary Disease Complicated by Heart Failure with Sanxiaotang

目的观察三小汤治疗慢性阻塞性肺疾病合并心力衰竭的临床疗效。方法将120例慢性阻塞性肺疾病合并心力衰竭的患者按不同的治疗方法分为三小汤治疗组(60例)和对照组(60例)。采用2014年GOLD中慢性阻塞性肺疾病及2014年中国心力衰竭诊断和治疗指南中的规范化治疗方案,治疗组在上述指南的规范化治疗方案联合三小汤,对照组给予上述指南规范化方案,观察2组患者临床疗效、肺功能改善情况以及检测血浆利钠肽治疗前后水平的变化。结果治疗组总有效率明显高于对照组(P<0.05),治疗组较对照组肺功能明显改善(P<0.05),治疗组血浆利钠钛(BNP)水平较对照组明显降低(P<0.05)。结论三小汤治疗慢性阻塞性肺疾病合并心力衰竭可明显改善患者临床疗效、肺功能水平及血浆利钠肽水平,三小汤具有显著改善慢性阻塞性肺疾病合并心力衰竭的临床疗效。

Objective To observe the clinical effect of Sanxiaotang on chronic obstructive pulmonary disease（COPD）complicated by heart failure.Methods A total of 120 patients with COPD and heart failure were divided into treatment group and control group,with 60 patients in each group.All patients were treated according to the standardized treatment regimens in 2014 GOLD and 2014 Chinese heart failure diagnosis and treatment guidelines.Additionally,the treatment group was given Sanxiaotang.Clinical efficacy,improvement in lung function and change in plasma natriuretic peptide level were observed in both groups.Results The total effective rate in treatment group was higher than that in control group（P〈0.05）.In addition,compared with control group,lung function was improved and plasma natriuretic peptide level was increased in treatment group（P〈0.05）.Conclusion The treatment with Sanxiaotang can significantly improve clinical efficacy,pulmonary function and plasma natriuretic peptide level in patients with COPD complicated by heart failure.